Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes—Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial
•There was a higher rate of treatment-related mortality with myeloablative conditioning, but this was offset by a much higher rate of relapse with reduced-intensity conditioning.•There was no difference in survival following relapse based on conditioning intensity.•Myeloablative conditioning led to...
Gespeichert in:
| Veröffentlicht in: | Transplantation and cellular therapy 2021-06, Vol.27 (6), p.483.e1-483.e6 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 483.e6 |
|---|---|
| container_issue | 6 |
| container_start_page | 483.e1 |
| container_title | Transplantation and cellular therapy |
| container_volume | 27 |
| creator | Scott, Bart L. Pasquini, Marcelo C. Fei, Mingwei Fraser, Raphael Wu, Juan Devine, Steve M. Porter, David L. Maziarz, Richard T. Warlick, Erica Fernandez, Hugo F. Soiffer, Robert J. Alyea, Edwin Hamadani, Mehdi Bashey, Asad Giralt, Sergio Geller, Nancy L. Leifer, Eric Hourigan, Christopher S. Gui, Gege Mendizabal, Adam Horowitz, Mary M. Deeg, H. Joachim Horwitz, Mitchell E. |
| description | •There was a higher rate of treatment-related mortality with myeloablative conditioning, but this was offset by a much higher rate of relapse with reduced-intensity conditioning.•There was no difference in survival following relapse based on conditioning intensity.•Myeloablative conditioning led to improved overall survival in patients with myelodysplastic syndrome or acute myelogenous leukemia who underwent allogeneic transplantation.
Several prospective randomized trials comparing conditioning intensity before allogeneic hematopoietic cell transplantation (HCT) have been performed, with conflicting results. Although reduced-intensity conditioning (RIC) leads to lower treatment-related mortality (TRM), this is offset by higher rates of relapse. Long-term follow-up of randomized comparative trials are limited. Here we present long-term follow-up of a randomized comparison of myeloablative conditioning (MAC) compared with RIC before HCT for acute myelogenous leukemia (AML) or myelodysplasia (MDS). Long-term comparative analyses of overall survival, relapse, and relapse-free survival were performed. Patients age 18 to 65 years with |
| doi_str_mv | 10.1016/j.jtct.2021.02.031 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2506506614</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2666636721007181</els_id><sourcerecordid>2506506614</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-97668756e8a0861c9d03019cf43f9c123b4af9e155916132b93968c32f487a273</originalsourceid><addsrcrecordid>eNp9ks1u1DAUhSMEolXpC7BAXrJJ6p_ESSSEVCJKK01Bguna8jg3Uw-OPdjOoNnxEH0v3oEnwWFKVTZIlmzpnvtd69yTZS8JLggm_GxTbKKKBcWUFJgWmJEn2THlnOec8frpo_dRdhrCBmNMS4YJw8-zI8bquuKkOs5-Xu_BOLkyMuodoB34MAX0GfpJQZ9f2Qg26LhHnbO9jtpZbddocB5dwiij2zoNUSvUgTFo6aUNWyNtlLMSaYvO1RQB_ZmxBusSegHTVxi1RNL2h0K_n5vCjPmyt713I4RfP-4Wzq7zJfgRXThj3Pf8ZovcgOItoHfXS9QtPyLcYoI6o61Wch6vpXmRPRukCXB6f59kNxfvl91lvvj04ao7X-SqrEjM25rzJlkAjcQNJ6rtcfKmVUPJhlYRylalHFogVdUSThhdtazljWJ0KJta0pqdZG8P3O20GqFXYKOXRmy9HqXfCye1-Ldi9a1Yu51oKKlZzRLg9T3Au28ThChGHVSyUVpIPglaYZ4OJ2WS0oNUeReCh-FhDMFiDoPYiDkMYg6DwFSkMKSmV48_-NDyd_VJ8OYggGTTToMXQWmwae3aQ4L1Tv-P_xtFq8qk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2506506614</pqid></control><display><type>article</type><title>Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes—Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Scott, Bart L. ; Pasquini, Marcelo C. ; Fei, Mingwei ; Fraser, Raphael ; Wu, Juan ; Devine, Steve M. ; Porter, David L. ; Maziarz, Richard T. ; Warlick, Erica ; Fernandez, Hugo F. ; Soiffer, Robert J. ; Alyea, Edwin ; Hamadani, Mehdi ; Bashey, Asad ; Giralt, Sergio ; Geller, Nancy L. ; Leifer, Eric ; Hourigan, Christopher S. ; Gui, Gege ; Mendizabal, Adam ; Horowitz, Mary M. ; Deeg, H. Joachim ; Horwitz, Mitchell E.</creator><creatorcontrib>Scott, Bart L. ; Pasquini, Marcelo C. ; Fei, Mingwei ; Fraser, Raphael ; Wu, Juan ; Devine, Steve M. ; Porter, David L. ; Maziarz, Richard T. ; Warlick, Erica ; Fernandez, Hugo F. ; Soiffer, Robert J. ; Alyea, Edwin ; Hamadani, Mehdi ; Bashey, Asad ; Giralt, Sergio ; Geller, Nancy L. ; Leifer, Eric ; Hourigan, Christopher S. ; Gui, Gege ; Mendizabal, Adam ; Horowitz, Mary M. ; Deeg, H. Joachim ; Horwitz, Mitchell E.</creatorcontrib><description>•There was a higher rate of treatment-related mortality with myeloablative conditioning, but this was offset by a much higher rate of relapse with reduced-intensity conditioning.•There was no difference in survival following relapse based on conditioning intensity.•Myeloablative conditioning led to improved overall survival in patients with myelodysplastic syndrome or acute myelogenous leukemia who underwent allogeneic transplantation.
Several prospective randomized trials comparing conditioning intensity before allogeneic hematopoietic cell transplantation (HCT) have been performed, with conflicting results. Although reduced-intensity conditioning (RIC) leads to lower treatment-related mortality (TRM), this is offset by higher rates of relapse. Long-term follow-up of randomized comparative trials are limited. Here we present long-term follow-up of a randomized comparison of myeloablative conditioning (MAC) compared with RIC before HCT for acute myelogenous leukemia (AML) or myelodysplasia (MDS). Long-term comparative analyses of overall survival, relapse, and relapse-free survival were performed. Patients age 18 to 65 years with <5% marrow myeloblasts were randomized to receive MAC (n = 135) or RIC (n = 137), followed by HCT from an HLA-matched donor. The primary endpoint of the trial was an 18-month pointwise comparison of overall survival. The analyses were performed using a proportional hazards model. The median follow-up of the entire cohort was 51 months. At 4 years, the transplant-related mortality (TRM) was 25.1% for MAC, compared with 9.9% for RIC (P < .001). Patients who received RIC had a significantly higher risk of relapse compared to those who received MAC (hazard ratio [HR], 4.06; 95% CI, 2.59 to 6.35; P < 0.001). Among the patients who relapsed after HCT, postrelapse survival was similar at 3 years (24% for MAC and 26% for RIC). Overall survival was superior for patients who received MAC compared to those who received RIC (HR, 1.54; 95% CI, 1.07 to 2.2; P = .03). Our data show that patients who received MAC were at higher risk of late TRM compared with those who received RIC; however, because of the exceedingly high rates of relapse in the RIC arm, overall survival remained significantly better for patients who received MAC. Among patients with MDS or AML eligible for either MAC or RIC regimens, long-term follow up demonstrates a survival advantage for patients who received MAC.</description><identifier>ISSN: 2666-6367</identifier><identifier>ISSN: 2666-6375</identifier><identifier>EISSN: 2666-6367</identifier><identifier>DOI: 10.1016/j.jtct.2021.02.031</identifier><identifier>PMID: 33775615</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acute myelogenous leukemia ; Adolescent ; Adult ; Aged ; Conditioning intensity ; Diterpenes ; Follow-Up Studies ; Hematopoietic cell transplantation ; Hematopoietic Stem Cell Transplantation ; Humans ; Leukemia, Myeloid, Acute - therapy ; Middle Aged ; Myelodysplastic syndrome ; Myelodysplastic Syndromes - therapy ; Prospective Studies ; Transplantation Conditioning ; Transplantation, Homologous ; Young Adult</subject><ispartof>Transplantation and cellular therapy, 2021-06, Vol.27 (6), p.483.e1-483.e6</ispartof><rights>2021</rights><rights>Copyright © 2021. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-97668756e8a0861c9d03019cf43f9c123b4af9e155916132b93968c32f487a273</citedby><cites>FETCH-LOGICAL-c451t-97668756e8a0861c9d03019cf43f9c123b4af9e155916132b93968c32f487a273</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33775615$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Scott, Bart L.</creatorcontrib><creatorcontrib>Pasquini, Marcelo C.</creatorcontrib><creatorcontrib>Fei, Mingwei</creatorcontrib><creatorcontrib>Fraser, Raphael</creatorcontrib><creatorcontrib>Wu, Juan</creatorcontrib><creatorcontrib>Devine, Steve M.</creatorcontrib><creatorcontrib>Porter, David L.</creatorcontrib><creatorcontrib>Maziarz, Richard T.</creatorcontrib><creatorcontrib>Warlick, Erica</creatorcontrib><creatorcontrib>Fernandez, Hugo F.</creatorcontrib><creatorcontrib>Soiffer, Robert J.</creatorcontrib><creatorcontrib>Alyea, Edwin</creatorcontrib><creatorcontrib>Hamadani, Mehdi</creatorcontrib><creatorcontrib>Bashey, Asad</creatorcontrib><creatorcontrib>Giralt, Sergio</creatorcontrib><creatorcontrib>Geller, Nancy L.</creatorcontrib><creatorcontrib>Leifer, Eric</creatorcontrib><creatorcontrib>Hourigan, Christopher S.</creatorcontrib><creatorcontrib>Gui, Gege</creatorcontrib><creatorcontrib>Mendizabal, Adam</creatorcontrib><creatorcontrib>Horowitz, Mary M.</creatorcontrib><creatorcontrib>Deeg, H. Joachim</creatorcontrib><creatorcontrib>Horwitz, Mitchell E.</creatorcontrib><title>Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes—Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial</title><title>Transplantation and cellular therapy</title><addtitle>Transplant Cell Ther</addtitle><description>•There was a higher rate of treatment-related mortality with myeloablative conditioning, but this was offset by a much higher rate of relapse with reduced-intensity conditioning.•There was no difference in survival following relapse based on conditioning intensity.•Myeloablative conditioning led to improved overall survival in patients with myelodysplastic syndrome or acute myelogenous leukemia who underwent allogeneic transplantation.
Several prospective randomized trials comparing conditioning intensity before allogeneic hematopoietic cell transplantation (HCT) have been performed, with conflicting results. Although reduced-intensity conditioning (RIC) leads to lower treatment-related mortality (TRM), this is offset by higher rates of relapse. Long-term follow-up of randomized comparative trials are limited. Here we present long-term follow-up of a randomized comparison of myeloablative conditioning (MAC) compared with RIC before HCT for acute myelogenous leukemia (AML) or myelodysplasia (MDS). Long-term comparative analyses of overall survival, relapse, and relapse-free survival were performed. Patients age 18 to 65 years with <5% marrow myeloblasts were randomized to receive MAC (n = 135) or RIC (n = 137), followed by HCT from an HLA-matched donor. The primary endpoint of the trial was an 18-month pointwise comparison of overall survival. The analyses were performed using a proportional hazards model. The median follow-up of the entire cohort was 51 months. At 4 years, the transplant-related mortality (TRM) was 25.1% for MAC, compared with 9.9% for RIC (P < .001). Patients who received RIC had a significantly higher risk of relapse compared to those who received MAC (hazard ratio [HR], 4.06; 95% CI, 2.59 to 6.35; P < 0.001). Among the patients who relapsed after HCT, postrelapse survival was similar at 3 years (24% for MAC and 26% for RIC). Overall survival was superior for patients who received MAC compared to those who received RIC (HR, 1.54; 95% CI, 1.07 to 2.2; P = .03). Our data show that patients who received MAC were at higher risk of late TRM compared with those who received RIC; however, because of the exceedingly high rates of relapse in the RIC arm, overall survival remained significantly better for patients who received MAC. Among patients with MDS or AML eligible for either MAC or RIC regimens, long-term follow up demonstrates a survival advantage for patients who received MAC.</description><subject>Acute myelogenous leukemia</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Conditioning intensity</subject><subject>Diterpenes</subject><subject>Follow-Up Studies</subject><subject>Hematopoietic cell transplantation</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>Leukemia, Myeloid, Acute - therapy</subject><subject>Middle Aged</subject><subject>Myelodysplastic syndrome</subject><subject>Myelodysplastic Syndromes - therapy</subject><subject>Prospective Studies</subject><subject>Transplantation Conditioning</subject><subject>Transplantation, Homologous</subject><subject>Young Adult</subject><issn>2666-6367</issn><issn>2666-6375</issn><issn>2666-6367</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9ks1u1DAUhSMEolXpC7BAXrJJ6p_ESSSEVCJKK01Bguna8jg3Uw-OPdjOoNnxEH0v3oEnwWFKVTZIlmzpnvtd69yTZS8JLggm_GxTbKKKBcWUFJgWmJEn2THlnOec8frpo_dRdhrCBmNMS4YJw8-zI8bquuKkOs5-Xu_BOLkyMuodoB34MAX0GfpJQZ9f2Qg26LhHnbO9jtpZbddocB5dwiij2zoNUSvUgTFo6aUNWyNtlLMSaYvO1RQB_ZmxBusSegHTVxi1RNL2h0K_n5vCjPmyt713I4RfP-4Wzq7zJfgRXThj3Pf8ZovcgOItoHfXS9QtPyLcYoI6o61Wch6vpXmRPRukCXB6f59kNxfvl91lvvj04ao7X-SqrEjM25rzJlkAjcQNJ6rtcfKmVUPJhlYRylalHFogVdUSThhdtazljWJ0KJta0pqdZG8P3O20GqFXYKOXRmy9HqXfCye1-Ldi9a1Yu51oKKlZzRLg9T3Au28ThChGHVSyUVpIPglaYZ4OJ2WS0oNUeReCh-FhDMFiDoPYiDkMYg6DwFSkMKSmV48_-NDyd_VJ8OYggGTTToMXQWmwae3aQ4L1Tv-P_xtFq8qk</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>Scott, Bart L.</creator><creator>Pasquini, Marcelo C.</creator><creator>Fei, Mingwei</creator><creator>Fraser, Raphael</creator><creator>Wu, Juan</creator><creator>Devine, Steve M.</creator><creator>Porter, David L.</creator><creator>Maziarz, Richard T.</creator><creator>Warlick, Erica</creator><creator>Fernandez, Hugo F.</creator><creator>Soiffer, Robert J.</creator><creator>Alyea, Edwin</creator><creator>Hamadani, Mehdi</creator><creator>Bashey, Asad</creator><creator>Giralt, Sergio</creator><creator>Geller, Nancy L.</creator><creator>Leifer, Eric</creator><creator>Hourigan, Christopher S.</creator><creator>Gui, Gege</creator><creator>Mendizabal, Adam</creator><creator>Horowitz, Mary M.</creator><creator>Deeg, H. Joachim</creator><creator>Horwitz, Mitchell E.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210601</creationdate><title>Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes—Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial</title><author>Scott, Bart L. ; Pasquini, Marcelo C. ; Fei, Mingwei ; Fraser, Raphael ; Wu, Juan ; Devine, Steve M. ; Porter, David L. ; Maziarz, Richard T. ; Warlick, Erica ; Fernandez, Hugo F. ; Soiffer, Robert J. ; Alyea, Edwin ; Hamadani, Mehdi ; Bashey, Asad ; Giralt, Sergio ; Geller, Nancy L. ; Leifer, Eric ; Hourigan, Christopher S. ; Gui, Gege ; Mendizabal, Adam ; Horowitz, Mary M. ; Deeg, H. Joachim ; Horwitz, Mitchell E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-97668756e8a0861c9d03019cf43f9c123b4af9e155916132b93968c32f487a273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acute myelogenous leukemia</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Conditioning intensity</topic><topic>Diterpenes</topic><topic>Follow-Up Studies</topic><topic>Hematopoietic cell transplantation</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>Leukemia, Myeloid, Acute - therapy</topic><topic>Middle Aged</topic><topic>Myelodysplastic syndrome</topic><topic>Myelodysplastic Syndromes - therapy</topic><topic>Prospective Studies</topic><topic>Transplantation Conditioning</topic><topic>Transplantation, Homologous</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Scott, Bart L.</creatorcontrib><creatorcontrib>Pasquini, Marcelo C.</creatorcontrib><creatorcontrib>Fei, Mingwei</creatorcontrib><creatorcontrib>Fraser, Raphael</creatorcontrib><creatorcontrib>Wu, Juan</creatorcontrib><creatorcontrib>Devine, Steve M.</creatorcontrib><creatorcontrib>Porter, David L.</creatorcontrib><creatorcontrib>Maziarz, Richard T.</creatorcontrib><creatorcontrib>Warlick, Erica</creatorcontrib><creatorcontrib>Fernandez, Hugo F.</creatorcontrib><creatorcontrib>Soiffer, Robert J.</creatorcontrib><creatorcontrib>Alyea, Edwin</creatorcontrib><creatorcontrib>Hamadani, Mehdi</creatorcontrib><creatorcontrib>Bashey, Asad</creatorcontrib><creatorcontrib>Giralt, Sergio</creatorcontrib><creatorcontrib>Geller, Nancy L.</creatorcontrib><creatorcontrib>Leifer, Eric</creatorcontrib><creatorcontrib>Hourigan, Christopher S.</creatorcontrib><creatorcontrib>Gui, Gege</creatorcontrib><creatorcontrib>Mendizabal, Adam</creatorcontrib><creatorcontrib>Horowitz, Mary M.</creatorcontrib><creatorcontrib>Deeg, H. Joachim</creatorcontrib><creatorcontrib>Horwitz, Mitchell E.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Transplantation and cellular therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Scott, Bart L.</au><au>Pasquini, Marcelo C.</au><au>Fei, Mingwei</au><au>Fraser, Raphael</au><au>Wu, Juan</au><au>Devine, Steve M.</au><au>Porter, David L.</au><au>Maziarz, Richard T.</au><au>Warlick, Erica</au><au>Fernandez, Hugo F.</au><au>Soiffer, Robert J.</au><au>Alyea, Edwin</au><au>Hamadani, Mehdi</au><au>Bashey, Asad</au><au>Giralt, Sergio</au><au>Geller, Nancy L.</au><au>Leifer, Eric</au><au>Hourigan, Christopher S.</au><au>Gui, Gege</au><au>Mendizabal, Adam</au><au>Horowitz, Mary M.</au><au>Deeg, H. Joachim</au><au>Horwitz, Mitchell E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes—Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial</atitle><jtitle>Transplantation and cellular therapy</jtitle><addtitle>Transplant Cell Ther</addtitle><date>2021-06-01</date><risdate>2021</risdate><volume>27</volume><issue>6</issue><spage>483.e1</spage><epage>483.e6</epage><pages>483.e1-483.e6</pages><issn>2666-6367</issn><issn>2666-6375</issn><eissn>2666-6367</eissn><abstract>•There was a higher rate of treatment-related mortality with myeloablative conditioning, but this was offset by a much higher rate of relapse with reduced-intensity conditioning.•There was no difference in survival following relapse based on conditioning intensity.•Myeloablative conditioning led to improved overall survival in patients with myelodysplastic syndrome or acute myelogenous leukemia who underwent allogeneic transplantation.
Several prospective randomized trials comparing conditioning intensity before allogeneic hematopoietic cell transplantation (HCT) have been performed, with conflicting results. Although reduced-intensity conditioning (RIC) leads to lower treatment-related mortality (TRM), this is offset by higher rates of relapse. Long-term follow-up of randomized comparative trials are limited. Here we present long-term follow-up of a randomized comparison of myeloablative conditioning (MAC) compared with RIC before HCT for acute myelogenous leukemia (AML) or myelodysplasia (MDS). Long-term comparative analyses of overall survival, relapse, and relapse-free survival were performed. Patients age 18 to 65 years with <5% marrow myeloblasts were randomized to receive MAC (n = 135) or RIC (n = 137), followed by HCT from an HLA-matched donor. The primary endpoint of the trial was an 18-month pointwise comparison of overall survival. The analyses were performed using a proportional hazards model. The median follow-up of the entire cohort was 51 months. At 4 years, the transplant-related mortality (TRM) was 25.1% for MAC, compared with 9.9% for RIC (P < .001). Patients who received RIC had a significantly higher risk of relapse compared to those who received MAC (hazard ratio [HR], 4.06; 95% CI, 2.59 to 6.35; P < 0.001). Among the patients who relapsed after HCT, postrelapse survival was similar at 3 years (24% for MAC and 26% for RIC). Overall survival was superior for patients who received MAC compared to those who received RIC (HR, 1.54; 95% CI, 1.07 to 2.2; P = .03). Our data show that patients who received MAC were at higher risk of late TRM compared with those who received RIC; however, because of the exceedingly high rates of relapse in the RIC arm, overall survival remained significantly better for patients who received MAC. Among patients with MDS or AML eligible for either MAC or RIC regimens, long-term follow up demonstrates a survival advantage for patients who received MAC.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>33775615</pmid><doi>10.1016/j.jtct.2021.02.031</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2666-6367 |
| ispartof | Transplantation and cellular therapy, 2021-06, Vol.27 (6), p.483.e1-483.e6 |
| issn | 2666-6367 2666-6375 2666-6367 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2506506614 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Acute myelogenous leukemia Adolescent Adult Aged Conditioning intensity Diterpenes Follow-Up Studies Hematopoietic cell transplantation Hematopoietic Stem Cell Transplantation Humans Leukemia, Myeloid, Acute - therapy Middle Aged Myelodysplastic syndrome Myelodysplastic Syndromes - therapy Prospective Studies Transplantation Conditioning Transplantation, Homologous Young Adult |
| title | Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes—Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T15%3A01%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Myeloablative%20versus%20Reduced-Intensity%20Conditioning%20for%20Hematopoietic%20Cell%20Transplantation%20in%20Acute%20Myelogenous%20Leukemia%20and%20Myelodysplastic%20Syndromes%E2%80%94Long-Term%20Follow-Up%20of%20the%20BMT%20CTN%200901%20Clinical%20Trial&rft.jtitle=Transplantation%20and%20cellular%20therapy&rft.au=Scott,%20Bart%20L.&rft.date=2021-06-01&rft.volume=27&rft.issue=6&rft.spage=483.e1&rft.epage=483.e6&rft.pages=483.e1-483.e6&rft.issn=2666-6367&rft.eissn=2666-6367&rft_id=info:doi/10.1016/j.jtct.2021.02.031&rft_dat=%3Cproquest_pubme%3E2506506614%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2506506614&rft_id=info:pmid/33775615&rft_els_id=S2666636721007181&rfr_iscdi=true |